Dermatology Tinley Park Robert J. Signore, DO, PC

wholisticderm.com

Home

about us

Most Frequent

How to get to us

Wart Immunotherapy

Photos-Wart Immunotherapy

Photos - Homeopathic

Homeopathic Derm Studies

New Patients Homeopathic

Natural Sunscreens

Natural Cosmetics

Contact Information

Disclaimer

                                      Candida Immunotherapy For Warts

     Common warts and plantar warts are viral infections caused by the human
papilloma virus.  Viral warts can be stubborn and difficult to get rid of.  When warts have failed the usual remedies, such as over-the-counter salicylic acid liquid or freezing with liquid nitrogen, then treatment with immunotherapy might be an appropriate next treatment.  Immunotherapy harnesses the body's natural healing energy by trying to fight the invading viral infection.

     Candida immunotherapy for warts was first described in Japan in 1978 by Seichi Harada, MD, who was professor of dermatology at the Nippon University School of Medicine in Tokyo.  In the 1980's, Ruth Bolton, MD pioneered the treatment for warts while at the University of Minnesota.  In the first few years of the new century, 3 groups in the U.S. published studies supporting the efficacy of Candida immunotherapy for warts:  Dr. John Pfenniger's group in Bay City, Michigan; the University of Arkansas (Dr. Sandra Marchese-Johnson, Dr. Thomas Horn and colleagues); and our office in Tinley Park, Illinois (Dr. Robert Signore, and staff).  Since then, this treatment for warts has become more widely used by dermatologists around the world.  

     During this form of immunotherapy, warts on the hands, fingers, feet, or toes are injected with a sterile solution called Candida albicans allergenic extract.  The warts often get itchy, or sore for 1 to 2 days after the injections.  Patients get these immunotherapy injections every 6 to 8 weeks until the warts are gone.  It is not uncommon for uninjected warts also to resolve during immunotherapy.  If the warts are not completely clear after 3 sessions, patients may select another form of treatment.  While this wart treatment is not always effective, we have seen patients' warts resolve dramatically with this form of immunotherapy even if they have failed other treatments, such as laser treatment, surgery, or  freezing.  
    
      While Candida allergenic extract has been FDA- approved since 1958 for injection into the skin for allergy immunotherapy and detection of allergic hypersensitivity, it is not FDA-approved for immunotherapy of warts yet.  Candida immunotherapy is an off-label use of Candida albicans allergenic extract.

     Side-effects include itching, localized soreness, swelling, and pain.  Chills and fever are uncommon, but usually respond to acetaminophen.  Hives or severe allergic reactions could be a rare possibility.   For safety reasons, in our office we pre-test suitable patients with a simple prick test of the forearm to detect severely hypersensitive patients prior to the first immunotherapy session.  

     You should NOT get Candida immunotherapy injections for your warts if:  you are pregnant or breast feeding, sick with a fever or the flu, are currently experiencing hives or a recent asthma attack, or have an active vaginal yeast infection, are taking immunosuppressant medicines, have a solid organ transplant, are taking beta-blocker medicines, or have had a previous allergic reaction to Candida albicans allergenic extract.

     You can discuss with our staff whether this treatment would be suitable for you at your office appointment.  We have found that Candida immunotherapy can be quite helpful in the treatment of common warts and plantar warts.  However, we have not found it helpful for flat warts.  

    


PUBLISHED REFERENCES - Candida albicans Intralesional Injection Immunotherapy of Warts:

1.  Signore RJ.  "Candida albicans Intralesional Injection Immunotherapy of Warts".  Cutis.  2002; volume 70: pages 185-192.

2.  Bellocchio S, Romani L, Covasciu C, Signore RJ.  "Candida albicans
Allergenic Extract Induces Toll-Like Receptor Expression and Increases Interferon-Alpha Production".  Pediatric Dermatology.  2006; volume 23:  number 5, pages 517-518. 


                                                Robert J. Signore, D.O., P.C.
                                                                               Dermatology
                                                           17730 S. Oak Park Avenue, Suite C
                                                                    Tinley Park, Illinois 60477
                                                                      (708) 429-2992 Phone
                                                                        (708) 429-3699 FAX

                           ©Copyright 2009-2012   Robert J. Signore, D.O., P.C.  -  All Rights Reserved